My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    LCL161
    LCL161

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0056
    CAS #: 1005342-46-0Purity ≥98%

    Description: LCL161 (LCL-161) is a novel and potent SMAC (second mitochondrial-derived activator of caspases) mimetic agent with potential anticancer activity, acting by potently binding to and inhibiting multiple IAP (inhibitor of apoptosis) proteins such as XIAP and c-IAP. It inhibits XIAP in HEK293 cells and cIAP1 in MDA-MB-231 cells with IC50s of 35 and 0.4 nM, respectively. LCL161 showed anti proliferative activities in two human hepatocellular carcinoma (HCC) cells, Hep3B and PLC5 with IC50 values of 10 and 19 μM, respectively. 

    References: Biochem Pharmacol. 2012 Aug 1;84(3):268-77; Pediatr Blood Cancer. 2012 Apr;58(4):636-9. 


    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)500.63
    FormulaC26H33FN4O3S
    CAS No.1005342-46-0
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: Soluble in DMSO > 10 mM
    Water: <1 mg/mL (slightly soluble or insoluble)
    Ethanol: 20 mg/mL warming (39.94 mM)
    Other info

    Synonym: LCL161; LCL 161; LCL-161

    Chemical Name: (S)-N-((S)-1-cyclohexyl-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide

    InChi Key: UFPFGVNKHCLJJO-SSKFGXFMSA-N

    InChi Code: InChI=1S/C26H33FN4O3S/c1-16(28-2)24(33)30-22(17-7-4-3-5-8-17)26(34)31-14-6-9-21(31)25-29-20(15-35-25)23(32)18-10-12-19(27)13-11-18/h10-13,15-17,21-22,28H,3-9,14H2,1-2H3,(H,30,33)/t16-,21-,22-/m0/s1

    SMILES Code: C[[email protected]](NC)C(N[[email protected]@H](C1CCCCC1)C(N2[[email protected]](C3=NC(C(C4=CC=C(F)C=C4)=O)=CS3)CCC2)=O)=O

    Chemical Name(2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In VitroLCL161 binds to inhibitors of apoptosis proteins (IAPs) with high affinity and initiates the destruction of cIAP1 and cIAP2, which further induces apoptosis via caspase activation. LCL161 modestly inhibits the growth of FLT3-ITD-expressing cells when administered alone, with an IC50 ranging from ~0.5 μM (Ba/F3-FLT3-ITD cells) to ~4 μM (MOLM13-luc+ cells).
    In VivoLCL161 significantly enhances the ability of PKC412 to inhibit the growth of Ba/F3-FLT3-ITD-luc+ cells in vivo. LCL161 is also shown to positively combine with the standard chemotherapeutic agents, Ara-c and doxorubicin, against FLT3-ITD-expressing cells and against D835Y-expressing cells. 
    Animal modelHuh-7 xeonograft nude mice
    Formulation & Dosage50 mg/kg; p.o.; q.d., for 20 days
    ReferencesBiochemical pharmacology, 2012, 84(3): 268-277.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    LCL161

    Weisberg E, et al. Leukemia, 2010, 24(12), 2100-2109.
     

    LCL161

    Effects of IAP inhibitor treatment and FLT3 inhibition, alone and combined, on the growth of mutant FLT3-expressing cells in vivo
     
    LCL161
    Effects of IAP inhibitor treatment and Abl inhibition, alone and combined, on the growth of BCR-ABL-expressing cells in vitro and in vivo


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?